VICTORIA, B.C., January 25, 2005 - CardioComm Solutions Inc. (TSX-V:CCG) (the "Company", "CardioComm"), is pleased to inform shareholders of a variety of significant events which occurred in their company during the course of the past year. In summary, it was a year of accomplishments. The Company sold more software than ever before; signed long term developments deals with industry leaders; won an award and other accolades from its peers; and significantly enhanced its marketing efforts on an international basis. Please find below an outline of such achievements:

• CardioComm posted record revenue growth in 2004 which was largely driven by strong U.S. performance and widespread industry recognition of the Company's software products. Preliminary numbers suggest the revenue recorded during fiscal 2004 will be approximately $2.7 million. This is up from $1.7 million the previous year.

• The Company announced its strongest Q1, Q2 and Q3 revenues ever recorded.

• The Company announced a partnership with Guidant Corporation in the development of its LATITUDET Patient Management System.

• CardioComm signed a Software License and Support Agreement with the Mayo Clinic. The agreement marked the second contract between the parties.

• The Company has expanded U.S. distribution channels through the signing of additional distributors and a manufacturer's representative program.

• In mid year the Company was honored with the Award for Innovative Excellence-Software and Software Distribution by Canadian based VIATeC organization.

• In Q4, the Company retained the Trout Group, a specialized New York based investor relations firm, to lead U.S. capital markets activity. The Company expects tangible results in early 2005.

• In December 2004, CardioComm launched GEMST 3.11 including HL7 Interface, the latest powerful upgrade for its popular cardiac software which contains over 25 enhanced features and capabilities.

In addition to the abovementioned, the Company is pleased to report the following:

• Subsequent to the end of the year, the Company is delighted to announce that Mr. Jon Darsee has joined CardioComm in a consultative role as Advisor, Business Development - Special Projects. Mr. Darsee was most recently the General Manager and Vice President of Instromedix and previously was Managing Director for Card Guard Europe. Mr. Darsee, now an industry consultant, brings more than 20 years of cardiovascular and telemedicine experience in the international marketplace to CardioComm to assist with strategic partnerships and other business relationships.

• The Company aims to continue to expand its distribution network by adding U.S. regional distribution through manufacturer's representatives and additional U.S. national and international distribution agreements.

• During 2004, the Company continued to focus on enhancing its GlobalCardioT marketing initiatives as a "recognized solution" for several significant international clients. International interest continues to be strong. Moving forward in 2005, CardioComm will continue to develop and invest in GlobalCardioT and other web-based solutions in ECG management marketplace.

• The Company will be moving into pilot projects both in the U.S. and internationally with cardiology centers doing referral services for primary care physicians.

About CardioComm Solutions Inc:

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System ( GEMST ) and GlobalCardioT . CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.